期刊文献+

西黄胶囊增强肺癌放化疗作用的临床疗效的观察 被引量:11

下载PDF
导出
摘要 观察局部放疗、小剂量化疗加中药西黄胶囊综合治疗中晚期肺癌患者的临床疗效,以及对临床症状、肿瘤缓解情况、生存期、生活质量的影响。方法:中晚期肺癌患者60例分为治疗组和对照组各30例,均接受局部放疗和小剂量化疗;治疗组加用西黄胶囊,20g/次,3次/d,2个月为1疗程。随访3~12个月,观察患者临床症状体征改善情况、肿瘤缓解情况和并发症发生率、生活质量等指标。结果:治疗组在临床症状、生存期、生活质量改善明显高于对照组。结论:提示中医中药加放、化疗综合治疗中晚期肺癌的疗效优于放化疗组,且更易为患者耐受,可在临床使用。
出处 《天津药学》 2007年第6期34-36,共3页 Tianjin Pharmacy
  • 相关文献

参考文献6

  • 1Cartei G, CarteiF, Camtone A, et al. Cisplatin - cyclophosphamide - mitomycin combination chemotherapy with supportive care versus supportive care alone for treatment of metastatic non small cel lung cancer . J Natl Cancer lnst, 1993,85:794.
  • 2Miyaji N, Oyama T, Uchiyama N, et al. Results of radiotherapy combined with BAi( bronchial artery infusion) for non -small cell lung cancer- analysis of 104 cases. Nippon Igaku Hoshasen Gakkai Zsshi(Japanese), 1991,51:270.
  • 3何欣,黄立中.犀黄丸临床应用及实验研究进展[J].湖南中医药导报,2003,9(4):82-84. 被引量:18
  • 4Belani C P. Combined modality therapy for unresectable stage Ⅲ non - small cell lung cancer: new chemotherapy combinations. Chest, 2000, 117(4) :127S.
  • 5白春学.肺癌的综合治疗[J].中国临床医学,2004,11(2):270-272. 被引量:4
  • 6李龙芸,穆新林.肺癌化疗进展[J].中国肺癌杂志,2003,6(6):450-455. 被引量:11

二级参考文献31

  • 1孙刚,姚健.犀黄丸治疗非化脓性肋软骨炎26例疗效观察[J].实用医学杂志,1989,5(3):44-44. 被引量:1
  • 2史青春,许丽杰,孙本林.四神丸合西黄丸治疗溃疡性结肠炎例[J].实用中医内科杂志,1994,8(1):23-24. 被引量:7
  • 3[1]Schiller JH. Influential papers since the last IASLC conference: cytotoxic therapy. Lung Cancer,2003,41(Suppl 3)∶S86.
  • 4[2]Socinski MA. Optimal number of cytotoxic agents and chemotherapy cycles for advanced NSCLC. Lung Cancer,2003, 41(Suppl 3)∶S93.
  • 5[3]Smith IE, O'Brien ME, Talbot DC, et al. Duration of chemotherapy in advanced non-small-cell lung cancer: a randomized trial of three versus six courses of mitomycin, vinblastine, and cisplatin. J Clin Oncol,2001,19(5)∶1336-1343.
  • 6[4]Socinski MA, Schell MJ, Peterman A, et al. Phase Ⅲ trial comparing a defined duration of therapy versus continuous therapy followed by second-line therapy in advanced-stage ⅢB/Ⅳ non-small-cell lung cancer. J Clin Oncol,2002,20(5)∶1335-1343.
  • 7[5]Depierre A, Quoix E, Mercier M, et al. Maintenance chemotherapy in advanced non-small cell lung cancer (NSCLC): A randomized study of vinorelbine (v) versus observation (ob) in patients (pts) responding to induction therapy (French Cooperative Oncology Group). Proc Am Soc Clin Onc,2001,20p∶309a.
  • 8[6]Fukuoka M. Epidermal growth factor receptor tyrosine kinase inhibitors: single agent therapy. Lung Cancer,2003,41(Suppl 3)∶S38.
  • 9[7]Goss G. Gefitinib ("Iressa"): The patients' experience. Lung Cancer,2003,41(Suppl 3)∶112.
  • 10[8]Herbst RS. Targeting the EGFR: prognostic and clinical implications. Lung Cancer,2003,41(Suppl 3)∶S114.

共引文献29

同被引文献159

引证文献11

二级引证文献104

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部